12-aminododecanoic acid: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
12-aminododecanoic acid : An omega-amino fatty acid that is dodecanoic acid in which one of the terminal amino hydrogens has been replaced by an amino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 69661 |
| CHEMBL ID | 371701 |
| CHEBI ID | 42025 |
| SCHEMBL ID | 35594 |
| MeSH ID | M0133601 |
| Synonym |
|---|
| einecs 211-754-7 |
| omega-aminododecanoic acid |
| 12-aminododecanoic acid |
| 12-aminolauric acid |
| ccris 6171 |
| 12-amino-dodecanoic acid |
| LMFA01100005 |
| 12-aminododecanoic acid, 95% |
| NCGC00164406-01 |
| 693-57-2 |
| A0932 |
| CHEMBL371701 |
| AKOS000121401 |
| unii-9042rp777g |
| ec 211-754-7 |
| 9042rp777g , |
| dodecanoic acid, 12-amino- |
| FT-0607230 |
| nh2-(ch2)11-cooh |
| 12-aminododecanic acid |
| SCHEMBL35594 |
| .lambda.-aminolauric acid |
| .omega.-aminolauric acid |
| .omega.-aminododecanoic acid |
| aminododecanoic acid, omega- |
| 5-nitro-naphthalene-1-carboxylicacidethylester |
| mfcd00008153 |
| CHEBI:42025 |
| omega-aminolauric acid |
| DTXSID90883480 |
| E76112 |
| AS-16036 |
| h-adod(12)-oh |
| BCP29358 |
| 12-aminolauric acid;h-12-ado-oh;nh2-(ch2)11-cooh;dodecanoicacid pound not12-amino- |
| Q27271277 |
| 12-aminododecanoic acid 100 microg/ml in acetonitrile:acetic acid |
| 25768-33-6 |
| EN300-21176 |
| CS-0158382 |
| BP-28234 |
| Role | Description |
|---|---|
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| omega-amino fatty acid | Any fatty acid n atoms long having an amino substituent at position n (omega). |
| medium-chain fatty acid | Any fatty acid with a chain length of between C6 and C12. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 44.6684 | 0.0002 | 21.2231 | 8,912.5098 | AID588515 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 10.0000 | 0.0023 | 19.5956 | 74.0614 | AID651743 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID255583 | Percent inhibition of CD40 expression in BCL1 cells treated with 10 uM peptide nucleic acid (PNA)conjugate; n=3 | 2005 | Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21 | Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid. |
| AID255581 | Percent inhibition of CD40 expression in BCL1 cells treated with 3 uM peptide nucleic acid (PNA)conjugate; n=3 | 2005 | Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21 | Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid. |
| AID255579 | Percent inhibition of CD40 expression in BCL1 cells treated with 1 uM peptide nucleic acid (PNA)conjugate; n=3 | 2005 | Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21 | Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.84) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||